GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics
GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics
QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC
Rusfertide shows promise for polycythemia vera treatment
CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer
Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC
EMUC 2024: Optimising strategies in mHSPC and mCRPC